Novo Nordisk and Eli Lilly took in a combined $36.2 billion from the global sale of GLP-1 drugs in the first nine months of 2024, underscoring the market allure for Chinese and Indian pharmaceutical companies
1 In type 2 diabetes, a separate phase 2 trial (Rosenstock and colleagues, published in The Lancet in 2023) randomized 281 adults with type 2 diabetes to retatrutide, the GLP-1 agonist dulaglutide as an active comparator, or placebo
Thank you, Samaritans Purse, for your provision, said Mrs
Freeze-dried: store at -20C for optimal long-term stability
Editorial: mortality and renal disease in type 1 diabetes mellitus-progress made, more to be done
its a highly researched, medically supervised option that leads to sustainable fat loss and reduced cravings